

**Supplementary Table 3.** Number of events and incidence data of patients receiving SGLT2is versus GLP1-RAs in the original cohort before IPTW

| Outcomes                                | SGLT2i (n=21,491) |                       |                  | GLP1-RAs (n=1,887) |                       |                  |
|-----------------------------------------|-------------------|-----------------------|------------------|--------------------|-----------------------|------------------|
|                                         | No. of events (%) | Total PY <sup>a</sup> | ID (95% CI)      | No. of events (%)  | Total PY <sup>a</sup> | ID (95% CI)      |
| <b>DR outcomes</b>                      |                   |                       |                  |                    |                       |                  |
| Any DR                                  | 536 (2.5)         | 35,639.0              | 15.0 (13.8–16.3) | 61 (3.2)           | 2,613.62              | 23.3 (17.5–29.2) |
| Non-proliferative DR                    | 435 (2.0)         | 35,769.0              | 12.2 (11.0–13.3) | 38 (2.0)           | 2,639.36              | 14.4 (9.8–19.0)  |
| Proliferative DR                        | 118 (0.55)        | 36,190.7              | 3.3 (2.7–3.9)    | 23 (1.2)           | 2,656.82              | 8.7 (5.1–12.2)   |
| <b>Vitreoretinal interventions</b>      |                   |                       |                  |                    |                       |                  |
| Intravitreal injection                  | 67 (0.31)         | 36,261.8              | 1.9 (1.4–2.3)    | 10 (0.53)          | 2,676.05              | 3.7 (1.4–6.1)    |
| Laser therapy                           | 136 (0.63)        | 36,173.6              | 3.8 (3.1–4.4)    | 25 (1.3)           | 2,662.73              | 9.4 (5.7–13.1)   |
| Vitrectomy                              | 47 (0.22)         | 36,267.0              | 1.3 (0.9–1.7)    | 8 (0.42)           | 2,673.65              | 3.0 (0.9–5.1)    |
| Composite surgical outcome <sup>b</sup> | 200 (0.93)        | 36,103.0              | 5.5 (4.8–6.3)    | 35 (1.9)           | 2,651.15              | 13.2 (8.8–17.6)  |
| <b>Microvascular complications</b>      |                   |                       |                  |                    |                       |                  |
| Diabetic nephropathy                    | 739 (3.4)         | 35,468.8              | 20.8 (19.3–22.3) | 91 (4.8)           | 2,581.70              | 35.3 (28.0–42.5) |
| Diabetic neuropathy                     | 253 (1.2)         | 36,057.8              | 7.02 (6.15–7.88) | 36 (1.9)           | 2,635.32              | 13.7 (9.2–18.1)  |
| <b>Macrovascular complications</b>      |                   |                       |                  |                    |                       |                  |
| Myocardial infarction                   | 142 (0.66)        | 36,206.0              | 3.9 (3.3–4.6)    | 17 (0.90)          | 2,675.93              | 6.4 (3.3–9.4)    |
| Ischemic stroke                         | 221 (1.0)         | 36,081.9              | 6.1 (5.3–6.9)    | 11 (0.6)           | 2,673.96              | 4.1 (1.7–6.5)    |
| Major adverse limb events <sup>c</sup>  | 233 (1.1)         | 36,039.1              | 6.5 (5.6–7.3)    | 15 (0.79)          | 2,666.20              | 5.6 (2.8–8.5)    |
| Cardiovascular death                    | 137 (0.64)        | 36,330.0              | 3.8 (3.1–4.4)    | 13 (0.69)          | 2,682.49              | 4.9 (2.2–7.5)    |

SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP1-RA, glucagon-like peptide-1 receptor agonist; IPTW, inverse probability of treatment weighting; PY, person-year; ID, incidence density; CI, confidence interval; DR, diabetic retinopathy.

<sup>a</sup>The number of events per 1,000 person-years, <sup>b</sup>Indicates any intravitreal injection, laser therapy, or vitrectomy, <sup>c</sup>Indicates any peripheral arterial disease, claudication, critical limb ischemia, endovascular therapy, peripheral bypass, or nontraumatic amputation.